| Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization M Korpal, BJ Ell, FM Buffa, T Ibrahim, MA Blanco, T Celià-Terrassa, ... Nature medicine 17 (9), 1101-1108, 2011 | 742 | 2011 |
| Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells T Celià-Terrassa, Ó Meca-Cortés, F Mateo, AM De Paz, N Rubio, ... The Journal of clinical investigation 122 (5), 1849-1868, 2012 | 525 | 2012 |
| Distinctive properties of metastasis-initiating cells T Celià-Terrassa, Y Kang Genes & development 30 (8), 892-908, 2016 | 346 | 2016 |
| Notch ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche R Chakrabarti, T Celià-Terrassa, S Kumar, X Hang, Y Wei, A Choudhury, ... Science 360 (6396), eaan4153, 2018 | 195 | 2018 |
| Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling M Shen, YZ Jiang, Y Wei, B Ell, X Sheng, M Esposito, J Kang, X Hang, ... Cancer cell 35 (1), 64-80. e7, 2019 | 181 | 2019 |
| Metastatic niche functions and therapeutic opportunities T Celià-Terrassa, Y Kang Nature cell biology 20 (8), 868-877, 2018 | 171 | 2018 |
| Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability T Celià-Terrassa, C Bastian, DD Liu, B Ell, NM Aiello, Y Wei, J Zamalloa, ... Nature communications 9 (1), 5005, 2018 | 160 | 2018 |
| Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis T Celià-Terrassa, MK Jolly Cold Spring Harbor perspectives in medicine 10 (7), a036905, 2020 | 134 | 2020 |
| Dynamics of phenotypic heterogeneity associated with EMT and stemness during cancer progression MK Jolly, T Celià-Terrassa Journal of clinical medicine 8 (10), 1542, 2019 | 117 | 2019 |
| Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis T Celià-Terrassa, DD Liu, A Choudhury, X Hang, Y Wei, J Zamalloa, ... Nature cell biology 19 (6), 711-723, 2017 | 103 | 2017 |
| Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program E Aguilar, I Marin de Mas, E Zodda, S Marin, F Morrish, V Selivanov, ... Stem cells 34 (5), 1163-1176, 2016 | 100 | 2016 |
| Acid ceramidase as a therapeutic target in metastatic prostate cancer [S] L Camacho, Ó Meca-Cortés, JL Abad, S García, N Rubio, A Díaz, ... Journal of lipid research 54 (5), 1207-1220, 2013 | 87 | 2013 |
| Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response M von Locquenghien, C Rozalén, T Celià-Terrassa The Journal of clinical investigation 131 (1), 2021 | 86 | 2021 |
| SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations F Mateo, Ó Meca-Cortés, T Celià-Terrassa, Y Fernández, I Abasolo, ... Molecular cancer 13, 1-17, 2014 | 82 | 2014 |
| Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy E Shirvani-Dastgerdi, BY Winer, T Celià-Terrassa, Y Kang, D Tabernero, ... Journal of hepatology 67 (2), 246-254, 2017 | 60 | 2017 |
| Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors EI Rivas, J Linares, M Zwick, A Gómez-Llonin, M Guiu, A Labernadie, ... Nature Communications 13 (1), 5310, 2022 | 42 | 2022 |
| LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer I Pérez-Núñez, C Rozalen, JÁ Palomeque, I Sangrador, M Dalmau, ... Nature cancer 3 (3), 355-370, 2022 | 42 | 2022 |
| p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis L Solé, T Lobo-Jarne, D Álvarez-Villanueva, J Alonso-Marañón, Y Guillén, ... Nature communications 13 (1), 2866, 2022 | 38 | 2022 |
| Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1 N Marques, M Sesé, V Cánovas, F Valente, R Bermudo, I De Torres, ... Oncogene 33 (9), 1124-1134, 2014 | 38 | 2014 |
| OVOL1/2: drivers of epithelial differentiation in development, disease, and reprogramming K Saxena, S Srikrishnan, T Celia-Terrassa, MK Jolly Cells Tissues Organs 211 (2), 183-192, 2022 | 32 | 2022 |
